Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
PRAX Stock Chart & Stats
$198.76
-$2.82(-3.64%)
At close: 4:00 PM EST
$198.76
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$26.70 - $206.71
Previous CloseN/A
Volume51.58K
Average Volume (3M)1.14M
Market Cap
$4.81B
Enterprise Value$602.50M
Total Cash (Recent Filing)$301.27M
Total Debt (Recent Filing)$755.00K
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Nov 05, 2025EPS Estimate
-3.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding24,191,414
10 Day Avg. Volume860,403
30 Day Avg. Volume1,135,787
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue77.59
Enterprise Value/Gross Profit78.53
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$285.36Price Target Upside43.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Market PotentialFollowing approval, there is potential for rapid uptake given the limited treatment options available to patients, with blockbuster status achievable.
Price Target IncreaseThe price target for PRAX was significantly increased from $61 to $251, reflecting higher confidence in the company's future prospects.
Regulatory ApprovalA pre-NDA meeting request to the FDA has been acknowledged, indicating progress towards regulatory approval.
Bears Say
Treatment Side EffectsDiscontinuations were mostly driven by dizziness and brain fog, which occurred during the initial weeks of treatment.
Trial ConcernsThere is risk in changing the primary endpoint of Study 1 from week 12 to week 8 without an explicit nod from the FDA.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $26.70 and its highest was $206.71 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $4.81B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 2 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Aug 04, 2025. The company reported -$3.31 earnings per share for the quarter, missing the consensus estimate of -$3.247 by -$0.063.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.47.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 24,191,414 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$3.31 in its last earnings report, missing expectations of -$3.247. Following the earnings report the stock price went down -5.546%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$285.36 (43.57% Upside)
$285.36 (43.57% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 111.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 57.6%
Last 30 Days ▲ 57.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.98%
12-Months-Change
Fundamentals
Return on Equity
-60.98%
Trailing 12-Months
Asset Growth
2.67%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX Company Deck
PRAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$285.36
▲(43.57% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
10.43% Insiders
16.19% Mutual Funds
2.09% Other Institutional Investors
57.82% Public Companies and Individual Investors